Search
PDF Archive search engine
Last database update: 25 February at 08:43 - Around 75000 files indexed.
Results for «paclitaxel»:
Total: 6 results - 0.02 seconds
v15n4S 57Revisiting 100%
The use of bevacizumab in combination with paclitaxel as first-line therapy for human epidermal growth factor receptor-2–negative metastatic breast cancer has been approved in more than 80 countries worldwide, including Hong Kong, Australia, the European Union, Korea, Malaysia, New Zealand, Switzerland, and Taiwan.
https://www.pdf-archive.com/2019/04/11/v15n4s57revisiting/
11/04/2019 www.pdf-archive.com
Luca Gianni 97%
Gianni has been involved in the development of paclitaxel in ovarian and breast cancer.
https://www.pdf-archive.com/2016/08/12/luca-gianni/
12/08/2016 www.pdf-archive.com
CV 86%
therapeutic implication NEW IDEA AWARD 2008 REGINA ELENA CANCER INSTITUTE (PI) - Exploratory Biomarkers study of phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy ASTRAZENECA 2009 (PI) Trials Clinici Principale Ricercatore Traslazionale Dr.ssa Anna Bagnato “A phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinumbased Chemotherapy” BIBLIOGRAFIA Castelli M., Guadagni S., Bagnato A., Pistoia M.A., Carboni M., Sega E.
https://www.pdf-archive.com/2017/09/14/cv/
14/09/2017 www.pdf-archive.com
eNERGY Protocole signe V2.0 2017.11.06 71%
40 • Carboplatin-paclitaxel ...................................................................................................................
https://www.pdf-archive.com/2017/11/14/energy-protocole-signe-v2-0-2017-11-06/
14/11/2017 www.pdf-archive.com
eNERGY NoteInfoConsentement V2.0 2017.11.06 47%
paclitaxel (90 mg/m2) avec carboplatine (AUC 6) avec une dose qui sera limitée à 700 mg, pendant 4 à 6 heures au Jour 1 de chaque cycle, puis paclitaxel (90/mg/m²) au Jour 8 et au Jour 15 de chaque cycle de 4 semaines, OU pemetrexed (500mg/m2) avec carboplatine (AUC 5) avec une dose qui sera limitée à 700 mg, pendant 4 à 6 heures au Jour 1 de chaque cycle de 3 semaines, Si votre maladie répond favorablement après 4 cycles de pemetrexed + carboplatine, le médecin-investigateur pourra vous proposer de poursuivre le pemetrexed seul, en cycles de 3 semaines, sans limite de durée tant que la maladie est contrôlée et que vous supportez bien ce traitement.
https://www.pdf-archive.com/2017/11/14/energy-noteinfoconsentement-v2-0-2017-11-06/
14/11/2017 www.pdf-archive.com
2016.01.04 08-10-48Reena Nair cv 2016 41%
Multicentre Study of a Cremophor ® - Free, Protein Stabilized, Nanoparticle Formulation of Paclitaxel (ABI-007) in-Patients with Stage IV Metastatic Breast Cancer’ sponsored by Quintiles Spectral (I) Ltd.
https://www.pdf-archive.com/2018/09/11/2016010408-10-48reena-nair-cv-2016/
11/09/2018 www.pdf-archive.com